Q4 and FY 2019 worldwide revenue is expected to be $114.4M and $390.3M, respectively.
Q4 and FY 2019 U.S. revenue is expected to be $97.9M and $326M, respectively.
Q4 U.S. trial procedure growth was 17% and permanent implant procedure growth was 20%.
Nevro expects FY 2020 worldwide revenue in the range of $435M to $440M.
The company plans to report final Q4 and FY 2019 results in February.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.